Loading organizations...
Qingkong SinoKing Capital functions as a diversified asset management firm, specializing in private equity and M&A funds. The firm strategically invests across information technology, new energy, new materials, and environmental protection sectors. It provides capital and financial tools to foster growth and development of its portfolio companies.
Established in 2013, SinoKing Capital operates as a key institution under the Qingkong Asset Management Group, affiliated with Tsinghua Holdings. Its founding insight integrated technology as a foundation with finance as a strategic tool. This model leverages Tsinghua's significant industrial, financial, and academic resources effectively.
SinoKing Capital primarily supports enterprises seeking strategic capital and M&A assistance within its targeted industries. Its vision is to cultivate markets through sophisticated financial solutions, guiding invested businesses towards sustained expansion and enhanced market positions globally.
Qingkong SinoKing Capital has 3 tracked investments across 2 companies. The latest tracked deal is $15.0M Series B in Zhiyi Pharmaceutics in July 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 7, 2022 | Zhiyi Pharmaceutics | $15.0M Series B | — | Guotou Chuangye, Korea Investment Partners |
| Dec 1, 2019 | Huaqin Communication Technology | $140.0M Series B | — | Intel Capital, China Merchants Bank, CMB International, Qualcomm Ventures, Wise Road Capital, Zhangjiang HI Tech |
| Dec 1, 2017 | Huaqin Communication Technology | $130.0M Series A | Intel Capital, HUA Capital | Northern Light Venture Capital, Walden International, Wise Road Capital |
